Judy's on the road, teaching other scientists how to successfully find XMRV. And judging from the rash of negative studies, this is an education that is sorely needed.
XMRV Global Action said:https://www.facebook.com/notes/xmrv-global-action/good-news-from-canada-strategies-for-detecting-xmrv-infection-in-clinical-sample/10150127271546797
Good News from Canada - Strategies for Detecting XMRV Infection in Clinical Samples
by XMRV Global Action on Friday, March 18, 2011 at 9:51am
Dr Judy Mikovits was in (snowy) Edmonton, Alberta, Canada today speaking on, Strategies for Detecting XMRV infection in clinical samples" to a packed room of scientists, hematologists and particularly Medical Microbiology and Immunology specialists, at the University of Alberta. Dr Andy Mason, co-author of the Commentary on the Lo/Alter FDA paper, was the host for this talk (http://www.aivi.med.ualberta.ca/ ).
XMRV Global Action was there for the 1 hour presentation, and the 1+ hrs of discussion with Judy and members of the Canadian XMRV team afterwards. The presentation was similar in content to the one given in Santa Rosa, however it was the audience composition, open and inquisitive tone of questions and new directions that made our reporters jaw drop. We have been asked not to report on this in detail, but suffice it to say Judys talk was very well received by this informed and open-minded scientific audience, and there are some very exciting happenings indeed, on the XMRV/MRV front in Canada.
We will most definitely post more if/when we have permission, but we respect the need to protect unpublished material. Until then, rest assured that work on XMRV/MRVs is ticking along very nicely indeed, and that Judy is as much in her element with patient audiences, as with academic/scientific audiences. Given the audience composition, it is especially notable that there was much appreciative nodding of heads and in the audience during the talk.
Our XMRV GA reporter will be comatose for a while from the trip, but rest assured well post more if/when we have explicit permission to do so. At the very least, well add some retrospective commentary when forthcoming work is published, and officially in the public domain.